C2N Diagnostics, LLC

Unilabs and C2N Diagnostics, LLC recently announced they inked a multi-year partnership agreement to increase access to the latter’s CE-marked Alzheimer’s tests in Europe, including Norway, Switzer

Over the last three years, researchers have made significant progress in defining key drivers of Alzheimer’s disease, which affects more than 50 million people worldwide. Tests such as a PET scan, MRI

The European approval process for Eisai Co., Ltd. / Biogen, Inc. ’s Alzheimer’s disease drug Leqembi (lecanemab) has been delayed due to the unprecedented impact from a recent court ruling related to

Eisai Co., Ltd. and its partner Biogen, Inc. crossed over the biggest barrier in their quest to commercialize Leqembi (lecanemab) now that Medicare will cover the cost of the Alzheimer’s disease dr